Mesenchymal Stem Cell Therapy in Pulmonary Disease
- Authors
- 이은주
- Issue Date
- Nov-2015
- Keywords
- 중간엽 줄기 세포; 치료 기전; 임상 시험; Mesenchymal stem cells; Mechanism; Clinical trials
- Citation
- 대한내과학회지, v.89, no.5, pp 522 - 526
- Pages
- 5
- Indexed
- KCI
- Journal Title
- 대한내과학회지
- Volume
- 89
- Number
- 5
- Start Page
- 522
- End Page
- 526
- URI
- https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/8346
- DOI
- 10.3904/kjm.2015.89.5.522
- ISSN
- 1738-9364
2289-0769
- Abstract
- Stem cells are undifferentiated cells that are clonal, self-renewing, and can differentiate into multiple cell types (known as potency). Among stem cells, there are embryonal stem cells, induced pluripotent stem cells, mesenchymal stem cells (MSCs), and hematopoietic stem cells. MSCs are fibroblast-like non-hematopoietic stem cells that can differentiate into various tissue types, including bone, muscle, liver, lung, and cartilage. MSCs can be isolated from bone marrow, adipose tissue, placenta, or umbilical cord blood, among other tissues. MSCs are adherent under tissue culture conditions and express several cell surface markers, including CD105, CD73, and CD90. However, MSCs show negative expression for CD45, CD34, CD14, CD11b, CD79α, CD19, and HLA-DR. This article aims to explain the current definition of MSCs, describe therapies for which MSCs may be used, and review recent lung disease clinical trials.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 2. Clinical Science > Department of Pulmonary, Allergy, and Critical Care Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.